Hydroformylation of alkenes is one of the most industrially important applications of transition metal catalysis. [1] Until recently, the most significant applications were focussed on linear selective hydroformylations of simple terminal alkenes, delivering aldehydes and products available from aldehydes for the commodity chemicals industry. For many years, the hydroformylation of more functionalised alkenes that would deliver the high-value products needed for organic synthesis was studied to a lesser degree, in part due to concerns regarding the control of regioselectivity, poor substrate scope and in the case of asymmetric catalysis, generally quite low enantioselectivity.[2] Consequently, asymmetric hydroformylation is under-exploited in organic synthesis, [3] despite the relatively recent discovery of some potentially useful enantioselective catalysts. [4][5][6][7][8][9][10][11][12][13][14] Enantioselective hydroformylation catalysts have generally been "benchmarked" for controlling selectivity in the hydroformylation of styrene derivatives and vinyl acetate. One of our objectives has been to demonstrate that this technology can be exploited in the synthesis of a wide range of useful chiral building blocks and hopefully encourage the widespread use of this potentially very clean, convenient and economic method for asymmetric C À C bond formation. Although internal alkenes can be sluggish hydroformylation substrates, strained alkenes often show good reactivity, as demonstrated by recent studies on the hydroformylation of norbornene and bicyclic hydrazines.[15] Therefore, we turned our interest to attempting hydroformylation of the bicyclic lactam azabicyclo-[2.2.1]hept-5-en-3-one (1) (see Scheme 1), because there is a significant demand for functionalised cyclopentylamines that potentially could be accessed by using this reaction. This demand arises from the widespread use of carbocyclic nucleoside analogues in medicinal chemistry;[16] a considerable range of compounds of this general type are biologically active, including clinically applied drugs and drug candidates, most notably, the widely applied nucleoside analogue reverse transcriptase inhibitor Abacavir, used to treat HIV and AIDS. In this communication, we report the successful enantioselective hydroformylation of a bicyclic lactam, and show two examples where the products can be easily converted into functionalised cyclopentylamines in enantiomerically pure form. [17] The enantiomerically pure bicyclic lactam 1 is produced very efficiently on a multi-tonne scale by Chirotech.[18] We began our study by investigating if there was any diastereocontrol when this substrate was subjected to hydroformylation either as the free amide or as the Boc-protected analogue (Boc = tert-butoxycarbonyl). These studies revealed that it was a straightforward substrate to hydroformylate in terms of reaction rate, and that the reaction is completely exo-selective, as determined by NOE NMR measurements (see the Supporting Information). The selectivity of the hydrofor...